Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR-mutated non-small cell lung cancer

被引：0
|
作者：
Aredo, Jacqueline V.
Urisman, Anatoly
Gubens, Matthew A.
Mulvey, Claire
Allen, Greg M.
Rotow, Julia K.
Kerr, Daniel Lucas
Chakrabarti, Turja
Bacaltos, Bianca
Gee, Megan
Jones, Kirk
Aisner, Dara L.
Patil, Tejas
Schenk, Erin Lynn
Bivona, Trever G.
Riess, Jonathan W.
Coleman, Melissa
Kratz, Johannes Ruediger
Jablons, David
Blakely, Collin M.
机构：
[1] Univ Calif San Francisco, San Francisco, CA USA
[2] Dana Farber Canc Inst, Boston, MA USA
[3] Univ Colorado, Aurora, CO USA
[4] Univ Colorado, Comprehens Canc Ctr, Aurora, CO USA
[5] Univ Colorado, Anschutz Med Campus, Aurora, CO USA
[6] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8508
引用
收藏
页数：1
相关论文
共 50 条
  • [21] First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer
    Jeong, Byeong-Ho
    Um, Sang-Won
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (03)
  • [22] Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
    Soria, J. -C.
    Ohe, Y.
    Vansteenkiste, J.
    Reungwetwattana, T.
    Chewaskulyong, B.
    Lee, K. H.
    Dechaphunkul, A.
    Imamura, F.
    Nogami, N.
    Kurata, T.
    Okamoto, I.
    Zhou, C.
    Cho, B. C.
    Cheng, Y.
    Cho, E. K.
    Voon, P. J.
    Planchard, D.
    Su, W. -C.
    Gray, J. E.
    Lee, S. -M.
    Hodge, R.
    Marotti, M.
    Rukazenkov, Y.
    Ramalingam, S. S.
    Boyer, Michael
    Lee, Chee
    Hughes, Brett
    O'Byrne, Kenneth
    Briggs, Peter
    Milward, Michael
    John, Thomas
    Demedts, Ingel
    Vansteenkiste, Johan
    Bustin, Frederique
    Barrios, Carlos Henrique
    Timcheva, Constanta
    Butts, Charles
    Goss, Glenwood
    Juergens, Rosalyn
    Leighl, Natasha
    Cheng, Susanna
    Burkes, Ronald
    Zhou, Caicun
    Zhang, Helong
    Shu, Yongqian
    Cheng, Ying
    Zhou, Qing
    Li, Wei
    Feng, Guosheng
    He, Yong
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02): : 113 - 125
  • [23] Treatment strategy of EGFR-mutated non-small cell lung cancer
    Tanaka, Fumihiro
    Yoneda, Kazue
    Takenaka, Masaru
    Kuroda, Koji
    JOURNAL OF THORACIC DISEASE, 2022, 14 (03) : 602 - 606
  • [24] Emerging drugs for EGFR-mutated non-small cell lung cancer
    Sukrithan, Vineeth
    Deng, Lei
    Barbar, Alexander
    Cheng, Haiying
    EXPERT OPINION ON EMERGING DRUGS, 2019, 24 (01) : 5 - 16
  • [25] How to Treat EGFR-Mutated Non-Small Cell Lung Cancer
    Belani, Neel
    Liang, Katherine
    Fradley, Michael
    Judd, Julia
    Borghaei, Hossein
    JACC: CARDIOONCOLOGY, 2023, 5 (04): : 542 - 545
  • [26] Systemic treatment of EGFR-mutated non-small cell lung cancer
    Czyzykowski, Rafal L.
    Wrona, Ewa K.
    Talajko, Agata
    Hasinska, Aleksandra M.
    Potemski, Piotr J.
    ONCOLOGY IN CLINICAL PRACTICE, 2024,
  • [27] Osimertinib in EGFR-Mutated Lung Cancer
    Liang, Wenhua
    Zhong, Ran
    He, Jianxing
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (07): : 675 - 675
  • [28] Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer
    Rao, Ding-Yu
    Huang, De-Fa
    Si, Mao-Yan
    Lu, Hua
    Tang, Zhi-Xian
    Zhang, Zu-Xiong
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [29] Evaluation of Pneumonitis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Receiving Osimertinib and Thoracic Radiation
    Mak, D. Y.
    Yan, M.
    Cheung, P.
    Parmar, A.
    Poon, I.
    Ung, Y.
    Tsao, M.
    Warner, A.
    Louie, A. V.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S497 - S497
  • [30] Pathological assessment of osimertinib-associated cardiotoxicity in EGFR-mutated non-small cell lung cancer patients
    Oka, T.
    Kamada, R.
    Kunimasa, K.
    Oboshi, M.
    Nishikawa, T.
    Yasui, T.
    Shioyama, W.
    Miyashita, Y.
    Koyama, T.
    Kumagai, T.
    Fujita, M.
    EUROPEAN HEART JOURNAL, 2020, 41 : 881 - 881
12345